Confirmed Sponsors & Exhibitors

Confirmed Sponsors

GOLD LEVEL

MedelaMedela Healthcare innovates and provides medical vacuum technology solutions for life-saving treatments and advancement of patient care. Thopaz+ takes chest drainage therapy to a new level of care. Unlike analogue systems it reliably regulates the applied pressure at the patient’s chest and digitally monitors critical therapy indicators. Clinical data has demonstrated that Medela’s chest drainage therapy improves outcomes and streamlines the delivery of care. Founded in 1961 by Olle Larsson and headquartered in Switzerland, Medela today is led by Michael Larsson.

Myriad Myriad myPlan® Lung Cancer is a molecular prognostic test that measures the expression of cell cycle progression genes to provide an accurate assessment of cancer aggressiveness in patients with early-stage non-small cell lung adenocarcinoma. Current medical society guidelines rely on cancer stage and subjective high risk features to determine lung cancer treatment. Two patients with the same lung cancer stage may have very different estimates of mortality risk when tumor aggressiveness is taken into account. MyPlan® Lung Cancer prognostic score combines molecular information with cancer stage to better predict the five-year risk of lung cancer-specific death than stage alone. Gaining insight into tumor aggressiveness will also help determine if surgery alone is sufficient, or if more aggressive treatment is needed.

BRONZE LEVEL

Bayer Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. Bayer’s oncology franchise now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.

Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, hepatitis C, HIV and rheumatoid arthritis. The Bristol-Myers Squibb Foundation’s philanthropic programs seek to promote health equity and improve the health outcomes among populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people.

Medtronic As a global leader in medical technology, services and solutions, Medtronic improves the lives and health of millions of people each year. We use our deep clinical, therapeutic, and economic expertise to address the complex challenges faced by healthcare systems today. Let’s take healthcare Further, Together. Learn more at Medtronic.com.

SUPPORTER LEVEL

Tyrogenex

Confirmed Exhibitors

BD Logo BD offers a comprehensive portfolio of products to help manage the symptoms associated with recurrent pleural effusions and ascites. The PleurX® catheter system helps patients manage recurrent pleural effusions and malignant ascites in the comfort of their own home. The Denver shunt is appropriate for malignant and non-malignant ascites patients, including those with chylous ascites, and helps maintain critical proteins and nutrients while relieving symptoms at home.

Halyard Logo Halyard Health is a medical technology company focused on preventing infection, eliminating pain and speeding recovery. One of Halyard’s products, the ON-Q* Pain Relief System reduces narcotic usage and provides better pain relief than narcotics alone in post-surgical patients. Patients who use ON-Q* went home an average of 1.1 days sooner, reported up to 69% lower pain scores and were up to three times as likely to report high satisfaction scores. For more info, visit www.halyardhealth.com

Intuitive Logo Intuitive Surgical is the global leader in minimally invasive, robotic-assisted surgery. Its da Vinci® System – with a 3D-HD vision system and EndoWrist® instrumentation – enables surgeons to offer a minimally invasive approach for a range of complex procedures. With more than 2,500 Systems installed in hospitals around the world, the da Vinci System is enabling surgeons to redefine the standard-of-care in a range of specialties: urology, gynecology, head and neck, general surgery, cardiac and thoracic surgery.

Medela Medela Healthcare innovates and provides medical vacuum technology solutions for life-saving treatments and advancement of patient care. Thopaz+ takes chest drainage therapy to a new level of care. Unlike analogue systems it reliably regulates the applied pressure at the patient’s chest and digitally monitors critical therapy indicators. Clinical data has demonstrated that Medela’s chest drainage therapy improves outcomes and streamlines the delivery of care. Founded in 1961 by Olle Larsson and headquartered in Switzerland, Medela today is led by Michael Larsson.

As a global leader in medical technology, services and solutions, Medtronic improves the lives and health of millions of people each year. We use our deep clinical, therapeutic, and economic expertise to address the complex challenges faced by healthcare systems today. Let’s take healthcare Further, Together. Learn more at Medtronic.com.

For 125 years, Merck has been a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook, YouTube and LinkedIn.

Myriad LogoMyriad myPlan® Lung Cancer is a molecular prognostic test that measures the expression of cell cycle progression genes to provide an accurate assessment of cancer aggressiveness in patients with early-stage non-small cell lung adenocarcinoma. Current medical society guidelines rely on cancer stage and subjective high risk features to determine lung cancer treatment. Two patients with the same lung cancer stage may have very different estimates of mortality risk when tumor aggressiveness is taken into account. MyPlan® Lung Cancer prognostic score combines molecular information with cancer stage to better predict the five-year risk of lung cancer-specific death than stage alone. Gaining insight into tumor aggressiveness will also help determine if surgery alone is sufficient, or if more aggressive treatment is needed.

ScanlanHighest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3000 titanium and stainless steel instrument designs. Full line SCANLAN® VATS Thoracoscopic instruments for multi-port and uniportal VATS procedures including – SCANLAN® D’Amico Clamps, Suctions and Biopsy Forceps; SCANLAN® Gonzalez-Rivas Dissector and Lung Grasper; Khan Decortication Grasper, SCANLAN® VATS Super Cut™ Scissors, Needle Holders, Forceps and Chitwood Knot Pusher. Selections available with finer shafts in shorter lengths for smaller frame patients.

Click here to download the ITMIG 2016 Exhibitor Manual (Last updated August 29, 2016)

Switch To Full Site